Core Viewpoint - The company,劲方医药-B (02595), announced the issuance and allocation of 13.386 million H-shares due to the full exercise of the over-allotment option on October 21, 2025 [1] Group 1 - The total number of H-shares issued is 13.386 million [1]

劲方医药-B(02595)发布公告，于2025年10月21日因超额配股权获悉数行使而发行及配发1338.6万股H 股。 ...

FF305 備註： 有關股份發行前的已發行股份數目為356,980,630股 (包括324,643,020股H股及32,337,610股未上市股份)。 第 2 頁 共 6 頁 v 1.3.0 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 勁方醫藥科技 ( 上海 ) 股份有限公司 （於中華人民共和國註冊成立的股份有限公司, 「本公司」） 呈交日期： 2025年10月21日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 普通股 | 股份類別 | H | | 於香港聯交所上市 | | 是 | | | | 證券代號 (如上 ...

Group 1 - Company GFH375 has shown promising results in treating KRAS G12D mutation pancreatic ductal adenocarcinoma (PDAC) patients, with a 40.7% objective response rate and a 96.7% disease control rate in a study presented at the ESMO annual meeting [1] - The median progression-free survival was reported at 5.52 months, with a 92.2% overall survival rate at 4 months for patients treated with GFH375 [1] - The KRAS G12D mutation is prevalent, affecting nearly 30% of KRAS mutations, indicating a significant unmet clinical need in the patient population [2] Group 2 - GFH375 has received FDA fast track designation and is approved for I/II clinical trials, targeting both first-line and subsequent treatments for locally advanced and metastatic KRAS G12D mutation PDAC patients [2] - The drug is a highly selective small molecule KRAS G12D inhibitor that disrupts the activation of downstream pathways, effectively inhibiting tumor cell proliferation [2] - A collaboration agreement has been established between the company and Verastem for the development of three RAS/MAPK-driven cancer products, with GFH375 being the lead project [3]

Core Insights - GFH375 has shown promising efficacy and safety in treating KRAS G12D mutation pancreatic ductal adenocarcinoma (PDAC) patients, with a reported objective response rate of 40.7% and a disease control rate of 96.7% [1][2] - The KRAS G12D mutation is prevalent, affecting nearly 30% of KRAS mutations, indicating a significant unmet clinical need in the patient population [2] - The collaboration between the company and Verastem for the development of GFH375 marks a strategic partnership aimed at expanding the drug's market reach outside of China [3] Group 1 - GFH375's clinical trial data presented at the ESMO 2025 conference highlighted its effectiveness in a cohort of 59 advanced PDAC patients, with a median progression-free survival of 5.52 months and a 4-month overall survival rate of 92.2% [1] - The drug has received FDA fast track designation and is set to enter I/II phase trials in June 2024, targeting both first-line and subsequent-line treatments for advanced KRAS G12D mutation PDAC patients [2] - The chief medical officer of the company emphasized the rapid clinical progress and the significant unmet needs of KRAS G12D mutation patients, indicating plans for further research in both subsequent and frontline treatments [2] Group 2 - GFH375 is an oral, highly selective small molecule KRAS G12D inhibitor that disrupts the activation of downstream pathways, effectively inhibiting tumor cell proliferation [2] - The partnership with Verastem grants exclusive rights to develop and commercialize GFH375 outside of Greater China, while the company retains rights within China [3] - The collaboration is contingent upon achieving predefined milestones in the I phase clinical trials, with GFH375 being the lead project for Verastem [3]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容引致的任何損失承擔任何責任。 GenFleet Therapeutics (Shanghai) Inc. 勁方醫藥科技（上海）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2595） 自願公告 KRAS G12D抑制劑GFH375治療晚期胰腺導管腺癌研究數據 呈列於2025年ESMO年會口頭報告及突破性研究摘要 本公告由勁方醫藥科技（上海）股份有限公司（「本公司」或「勁方」，連同其附屬公 司統稱「本集團」）自願刊發，以知會本公司股東及潛在投資者有關本集團最新業 務動態。 本公司董事會欣然宣佈，GFH375單藥治療KRAS G12D突變型胰腺導管腺癌 (PDAC)患者數據於德國當地時間10月19日登陸2025年歐洲腫瘤內科學會(ESMO) 年會的突破性研究摘要(LBA)和口頭報告。此次口頭報告由中國醫學科學院腫 瘤醫院周愛萍教授完成，該報告標題為「GFH375治療經治晚期KRAS G12D突 變型PDAC患者的療效 ...

Core Insights - The company, Jinfang Pharmaceutical-B (02595), announced that the sole sponsor and overall coordinator has fully exercised the over-allotment option as of October 16, 2025, involving a total of 13.386 million H-shares, which represents approximately 15% of the total shares available for subscription before the exercise of any over-allotment options [1] - The over-allotment shares will be issued at a price of HKD 20.39 per H-share and will be used to cover the excess allocation in the international offering [1] - The stabilization period for the global offering ended on October 16, 2025, which is 30 days after the submission deadline for the Hong Kong public offering application [1]

Core Viewpoint - The company, Jinfang Pharmaceutical-B (02595.HK), announced that its sole sponsor and overall coordinator has fully exercised the over-allotment option as stated in the prospectus, involving a total of 13,386,000 H-shares, which accounts for approximately 15% of the total shares available for subscription before the exercise of any over-allotment option [1] Group 1 - The over-allotment shares will be issued at a price of HKD 20.39 per H-share, which is the same as the global offering price, excluding various fees [1] - The over-allotment shares will be used to cover the excess allocation in the international offering [1] - The stabilization period for the global offering has ended on October 16, 2025, which is the 30th day after the submission deadline for the Hong Kong public offering application [1]

智通财经APP讯，劲方医药-B(02595)发布公告，独家保荐人兼整体协调人(为其本身及代表国际包销商) 已于2025年10月16日悉数行使招股章程所述的超额配股权，涉及合共1338.6万股H股，占于任何超额配 股权获行使前全球发售项下可供认购发售股份总数约15%(经计及发售量调整权获悉数行使)。超额配发 股份将由公司按每股H股20.39港元发行及配发。超额配发股份将用于补足国际发售的超额分配。 此 外，有关全球发售的稳定价格期已于2025年10月16日(即递交香港公开发售申请截止日期后第30日)结 束。 ...

香港交易及結算所有限公司、香港聯合交易所有限公司（「聯交所」）及香港中央結算有限公司對 本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告 全部或任何部分內容而產生或因依賴該等內容引致的任何損失承擔任何責任。 本公告不會直接或間接在或向美國（包括其領土及屬地、美國任何州以及哥倫比亞特區）發佈、 刊發或派發。本公告並非亦無意構成或組成於美國或任何其他司法管轄區購買或認購證券的任 何要約或招攬的一部分。本公告所述證券不曾亦不會根據1933年美國證券法（經不時修訂）（「美 國證券法」）或美國任何州或其他司法管轄區的證券法登記。證券不得在美國境內提呈發售、出 售、抵押或轉讓，惟獲豁免遵守或毋須遵守美國證券法登記規定及任何適用的州證券法的交易 除外。證券將不會於美國進行公開發售。證券僅可(1)根據美國證券法的登記豁免向合資格機構 買家（定義見美國證券法第144A條）；及(2)根據美國證券法S規例以及進行發售及出售的各司法 管轄區適用法律在美國境外以離岸交易方式提呈發售及出售。 本公告僅供參考，並不構成收購、購買或認購證券的邀請或要約。有關發售股份的任何投資 決定應僅根據招股章程中的資料作 ...